ParkinsonCanadaV1, Main, Exploration, bibRecord, 001021

Biomarkers for trials of neuroprotection in Parkinson's disease

Identifieur interne : 001021 ( Main/Exploration ); précédent : 001020; suivant : 001022

Biomarkers for trials of neuroprotection in Parkinson's disease

Auteurs : Pankaj A. Agarwal [Canada] ; A. Jon Stoessl [Canada]

Source :

Movement Disorders [ 0885-3185 ] ; 2013-01.

RBID : ISTEX:07F59C467FC0683976CDE07244A017B4B0867BCD

English descriptors

KwdEn :
- Animals, Biomarkers (metabolism), Brain (metabolism), Brain (pathology), Disease Progression, Dopamine (metabolism), Essential Tremor (diagnosis), Humans, Neuroimaging, Neuroprotective Agents (therapeutic use), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (metabolism).
MESH :
- chemical , metabolism : Biomarkers, Dopamine.
- diagnosis : Essential Tremor, Parkinson Disease.
- drug therapy : Parkinson Disease.
- metabolism : Brain, Parkinson Disease.
- pathology : Brain.
- chemical , therapeutic use : Neuroprotective Agents.
- Animals, Disease Progression, Humans, Neuroimaging.

Abstract

With increased understanding of disease pathogenesis and the foreseeable reality of disease‐modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions. © 2013 Movement Disorder Society

Url:

https://api-v5.istex.fr/document/07F59C467FC0683976CDE07244A017B4B0867BCD/fulltext/pdf

DOI: 10.1002/mds.25065

Affiliations:

Canada

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Biomarkers for trials of neuroprotection in Parkinson's disease</title>
<author><name sortKey="Agarwal, Pankaj A" sort="Agarwal, Pankaj A" uniqKey="Agarwal P" first="Pankaj A." last="Agarwal">Pankaj A. Agarwal</name>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:07F59C467FC0683976CDE07244A017B4B0867BCD</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/mds.25065</idno>
<idno type="url">https://api-v5.istex.fr/document/07F59C467FC0683976CDE07244A017B4B0867BCD/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000152</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000152</idno>
<idno type="wicri:Area/Istex/Curation">000152</idno>
<idno type="wicri:Area/Istex/Checkpoint">000139</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000139</idno>
<idno type="wicri:doubleKey">0885-3185:2013:Agarwal P:biomarkers:for:trials</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:22927101</idno>
<idno type="wicri:Area/PubMed/Corpus">000987</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000987</idno>
<idno type="wicri:Area/PubMed/Curation">000987</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000987</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000987</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000987</idno>
<idno type="wicri:Area/Ncbi/Merge">001233</idno>
<idno type="wicri:Area/Ncbi/Curation">001233</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001233</idno>
<idno type="wicri:Area/Main/Merge">001033</idno>
<idno type="wicri:Area/Main/Curation">001021</idno>
<idno type="wicri:Area/Main/Exploration">001021</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Biomarkers for trials of neuroprotection in Parkinson's disease</title>
<author><name sortKey="Agarwal, Pankaj A" sort="Agarwal, Pankaj A" uniqKey="Agarwal P" first="Pankaj A." last="Agarwal">Pankaj A. Agarwal</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, British Columbia, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Vancouver Costal Health, British Columbia, Vancouver</wicri:regionArea>
<wicri:noRegion>Vancouver</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov Disord</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<date type="published" when="2013-01">2013-01</date>
<biblScope unit="volume">28</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="71">71</biblScope>
<biblScope unit="page" to="85">85</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">07F59C467FC0683976CDE07244A017B4B0867BCD</idno>
<idno type="DOI">10.1002/mds.25065</idno>
<idno type="ArticleID">MDS25065</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Biomarkers (metabolism)</term>
<term>Brain (metabolism)</term>
<term>Brain (pathology)</term>
<term>Disease Progression</term>
<term>Dopamine (metabolism)</term>
<term>Essential Tremor (diagnosis)</term>
<term>Humans</term>
<term>Neuroimaging</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Biomarkers</term>
<term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Essential Tremor</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Progression</term>
<term>Humans</term>
<term>Neuroimaging</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">With increased understanding of disease pathogenesis and the foreseeable reality of disease‐modifying therapies, there is a growing need to find biomarkers that will allow early (preferably preclinical) detection of disease and that will provide an independent readout of disease progression. In this article, we review a variety of markers, with a focus on functional imaging techniques, which while imperfect, currently provide the best approach to this problem. We consider the limitations of functional imaging of the dopamine system in assessing the progression of Parkinson's Disease (PD) as well as the potential use of structural imaging and emerging progress in other biochemical and molecular markers. While there is no single biomarker that will satisfy all requirements, some combination is likely to be of great use in identifying those subjects most likely to benefit from neuroprotective therapies, as well as in monitoring the effects of these interventions. © 2013 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Agarwal, Pankaj A" sort="Agarwal, Pankaj A" uniqKey="Agarwal P" first="Pankaj A." last="Agarwal">Pankaj A. Agarwal</name>
</noRegion>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001021 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001021 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:07F59C467FC0683976CDE07244A017B4B0867BCD
   |texte=   Biomarkers for trials of neuroprotection in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Biomarkers for trials of neuroprotection in Parkinson's disease

Biomarkers for trials of neuroprotection in Parkinson's disease

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.